57 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 57 of 57 clinical reviews.
A complete guide to Aetna (CVS Health) coverage for generic tadalafil, including formulary tier, prior authorization criteria, step therapy requirements, appeal strategies, and real out-of-pocket cost comparisons.
UnitedHealthcare typically covers generic tadalafil on Tier 3 with prior authorization. Learn formulary placement, PA criteria, step therapy rules, appeal steps, and cost-saving strategies.
Evidence-based guidance on stopping tadalafil 2.5-20 mg safely, including when tapering matters, what symptoms to expect, and how to manage the return of ED or BPH symptoms after discontinuation.
Tadalafil is not FDA-approved for erectile dysfunction or BPH in patients aged 12-17. This article reviews the limited evidence, off-label considerations, and the one pediatric indication where tadalafil data does exist.
A guide to monitoring tadalafil 2.5 to 20 mg in adults aged 30 to 49: when to check blood pressure, PSA, liver enzymes, and cardiovascular risk, with dose-specific safety thresholds and follow-up intervals.
Evidence-based tadalafil dosing guide for adults aged 30-49, covering daily low-dose and on-demand protocols for erectile dysfunction and BPH.
Tadalafil is an oral PDE5 inhibitor for ED and BPH. Learn how it works, when it fails, and how intracavernosal injection (ICI) therapy serves as the evidence-based next step, including full self-injection technique.
A cautious, FDA-label-anchored guide to tadalafil 2.5 to 20 mg dosing limits, interaction risk, and safety considerations for patients with autoimmune conditions including lupus, rheumatoid arthritis, systemic sclerosis, and inflammatory bowel disease.
A deep dive into how tadalafil 2.5 to 20 mg affects bone mineral density, fracture risk, and skeletal metabolism. Covers PDE5 inhibitor mechanisms, key trials, and practical prescribing guidance.
A comprehensive MD/PharmD-level review of tadalafil 2.5 to 20 mg and cancer risk signals, covering PDE5-inhibitor biology, epidemiological data, bladder and prostate cancer considerations, and current clinical guidance for prescribers.
A physician-level review of tadalafil's long-term cardiovascular effects, covering hemodynamics, heart failure data, drug interactions, and safety in men with ED and BPH.
A deep dive into tadalafil's effects on cognitive function, cerebral blood flow, and neuroinflammation. Covers doses 2.5 to 20 mg, key clinical trials, and practical prescribing guidance.
A practical guide to clinically significant tadalafil drug interactions, from absolute contraindications with nitrates to CYP3A4-mediated dosing cautions, organized by what a prescriber or patient actually needs to decide.
Compare the cost of generic tadalafil against sildenafil, vardenafil, and avanafil. Includes pricing context, clinical efficacy data, and guidance on choosing among PDE5 inhibitors.
How to dose generic tadalafil for adults aged 50 to 64, including daily vs. on-demand protocols, drug interactions, cardiovascular screening, and BPH overlap.
A guide to tadalafil 2.5 to 20 mg dosing for men aged 18 to 29, covering on-demand vs. daily regimens, fertility considerations, BPH overlap, safety, and a clinician-discussion framework for monitoring.
Evidence-based guidance on tadalafil 2.5 to 20 mg dosing adjustments for patients with Child-Pugh A, B, and C hepatic impairment. Covers pharmacokinetics, safety, and prescribing recommendations backed by FDA labeling and primary literature.
Evidence-based guide to tadalafil dose adjustments in kidney disease, covering mild, moderate, and severe renal impairment plus dialysis patients, with FDA label data and primary-source citations.
Evidence-based guide to tadalafil food and supplement interactions, including grapefruit, alcohol, L-arginine, St. John's Wort, and CYP3A4 pathways, with sourcing limits clearly marked.
Evidence-based guide to tadalafil dosing in older adults (65+), covering starting doses, renal adjustments, drug interactions, fall risk, and BPH considerations.
A deep dive into tadalafil's effects on hair and skin, covering the pharmacology, clinical trial data, and practical guidance for patients on 2.5 to 20 mg daily or on-demand dosing.
A deep dive into how tadalafil 2.5 to 20 mg was discovered, developed, and approved, covering mechanism, key clinical trials, and what generic availability means for patients today.
Evidence-based guide to prescribing generic tadalafil in transplant recipients, HIV-positive patients, chronic kidney disease, hepatic impairment, spinal cord injury, diabetes, and post-prostatectomy populations.
A deep dive into how tadalafil 2.5 to 20 mg affects liver function, including pharmacokinetics, hepatic metabolism, clinical trial safety data, and dosing guidance for patients with liver disease.
A clinical review of generic tadalafil's manufacturing base, FDA supply chain data, and documented shortage episodes from patent expiry through 2026.
A clinical deep-dive into how tadalafil 2.5 to 20 mg affects mental health, mood, anxiety, and depression, covering trial data, mechanisms, and prescribing considerations.
How tadalafil 2.5 to 20 mg is absorbed, metabolized via CYP3A4, and cleared, plus the emerging evidence linking PDE5 inhibition to thermogenesis, mitochondrial biogenesis, and metabolic outcomes in humans.
A guide to the complete monitoring schedule for generic tadalafil (2.5 to 20 mg) covering baseline labs, cardiovascular screening, follow-up exams, drug interactions, and special populations.
A guide to how tadalafil 2.5 to 20 mg supports skeletal muscle preservation, the mechanisms involved, dosing considerations, and how to combine it with exercise and hormone therapy for maximum benefit.
A guide to tadalafil's off-label applications beyond ED and BPH, graded by clinical evidence from RCTs, meta-analyses, and guideline endorsements.
A guide to monitoring tadalafil 2.5 to 20 mg in adults aged 50, 64, covering cardiovascular safety, drug interactions, BPH/ED overlap, andropause, and lab checkpoints with primary-source citations.
Evidence-based guide to tadalafil overdose recognition, pharmacokinetics at supratherapeutic doses, and supportive management. Covers accidental double-dosing, intentional excess, and when to seek emergency care.
Tadalafil has no FDA-approved pediatric indication for children under 12. This evidence review covers off-label dosing research in pulmonary arterial hypertension, safety data, and monitoring requirements for prescribing clinicians.
Evidence-based guide to monitoring tadalafil in pediatric patients under 12, covering off-label PAH use, weight-based dosing, hepatic surveillance, hemodynamic tracking, and growth assessment.
An evidence-based review of tadalafil (generic) safety in pediatric patients under 12, covering FDA labeling, the STARTS trials, off-label risks, weight-based dosing considerations, and monitoring protocols.
How CYP3A4, CYP3A5, and PDE5A polymorphisms influence tadalafil metabolism, efficacy, and side-effect risk. Evidence-based guidance for clinicians considering pharmacogenomic testing.
Why tadalafil stops working, how to identify the cause, and the clinical steps to restore response. MD/PharmD-level guidance on dose optimization, timing errors, drug interactions, and when to escalate.
What is established, and what is not, about generic tadalafil (2.5 to 20 mg) after bariatric surgery, covering plausible pharmacokinetic changes, dose selection tradeoffs, drug interactions, and monitoring for ED and BPH indications.
Complete clinical guide to the tadalafil pre-surgery hold window: how long to stop tadalafil before any procedure, why the pharmacology demands it, and how to manage BPH/ED patients perioperatively.
Is tadalafil safe during pregnancy or breastfeeding? Review FDA labeling, animal reproductive data, human evidence, and clinical guidance for tadalafil in reproductive contexts.
A clinical review of real-world evidence for generic tadalafil 2.5-20 mg across erectile dysfunction and BPH, including registry studies, claims analyses, and post-market safety data.
A guide on what happens when you stop tadalafil (generic, 2.5 to 20 mg), covering rebound ED, BPH symptom return, cardiovascular considerations, and how to taper safely based on current clinical evidence.
A clinician-level breakdown of how generic tadalafil 2.5 to 20 mg is regulated across the United States, European Union, Canada, and the United Kingdom, including approval dates, scheduling, and prescribing implications.
Does tadalafil protect the kidneys or harm them? This MD/PharmD-level review covers the pharmacology, clinical trial data, dosing in CKD, and safety profile of generic tadalafil 2.5 to 20 mg for erectile dysfunction and BPH.
A guide to tadalafil 2.5 to 20 mg safety for adults aged 30, 49, covering contraindications, drug interactions, cardiovascular risk, side effects, and dosing guidance backed by trial data.
Evidence-based safety guide for generic tadalafil (2.5-20 mg) in adults aged 50-64, covering cardiovascular risks, drug interactions, dose adjustments, and monitoring protocols.
A clinical review of tadalafil generic safety in men aged 18 to 29, covering dosing, side effects, cardiovascular risk, fertility, and long-term use considerations.
Evidence-based review of tadalafil (generic) safety considerations for adolescents aged 12-17, including off-label use, pharmacokinetics, monitoring protocols, and clinical guidance.
FDA labeling lists organic nitrates as an absolute contraindication with tadalafil; nitrates must be deferred at least 48 hours after a tadalafil dose.
A clinician-level guide to how temperature, humidity, altitude, and seasonal health patterns affect tadalafil 2.5 to 20 mg dosing, storage, and efficacy for ED and BPH-LUTS.
How to store generic tadalafil 2.5 to 20 mg correctly, what the stability data shows, when tablets degrade, and what that means for efficacy and safety, with PubMed and FDA citations.
A clinician-level guide to switching between tadalafil, sildenafil, vardenafil, and avanafil, covering pharmacology, timing, dosing, and real trial data to help patients and prescribers make safe, effective transitions.
A guide to tadalafil dosing during long-haul travel, jet lag, and timezone shifts, covering daily and as-needed regimens for ED and BPH.
A clinical review of emerging tadalafil formulations, novel delivery systems, combination therapies, and pipeline developments beyond the standard 2.5-20 mg oral tablet.
What tadalafil's U.S. label and clinical trials say about 2.5 mg and 5 mg once-daily dosing, how daily use differs from as-needed use, and which safety gates matter.
A clinical deep-dive into tadalafil's patent expiration, Paragraph IV challenges, and the generic timeline from 2017 onward, with FDA and trial-cited evidence.
Tadalafil reaches peak plasma at about 2 hours post-dose, with 80% bioavailability and a 17.5-hour half-life per FDA label pharmacokinetic data.